EndoClear™ Plus human recombinant a-Synuclein protein

Overview

The EndoClear™ Plus human recombinant a-Synuclein protein is essential for those studying Parkinson’s disease and its underlying mechanisms. As a significant component of Lewy bodies found in neurons affected by this condition, understanding a-Synuclein is vital for developing therapeutic strategies. This protein is primarily found in the brain, particularly in regions like the cerebellum, thalamus, neocortex, hippocampus, and striatum, where its expression plays a potential role in neurodegeneration.

Key Features

• Human recombinant a-Synuclein, ideal for research applications
• Critical for studies focused on Parkinson’s disease
• Available in a highly purified form for accurate results
• Supports investigations into the physiological role of a-Synuclein
• Contributes to understanding neurodegenerative diseases

Specifications

FAQ

What is the role of a-Synuclein in Parkinson’s disease?

a-Synuclein is a protein that accumulates in Lewy bodies, which are abnormal aggregates found in the brains of individuals with Parkinson’s disease. Its aggregation is thought to play a crucial role in the disease’s progression.

How is the EndoClear™ Plus protein purified?

This product undergoes advanced purification processes to ensure that the a-Synuclein protein is highly pure (>95%), making it suitable for various experimental applications.

What are common applications for this protein?

The EndoClear™ Plus human recombinant a-Synuclein protein is used in a variety of research applications, including studies of neurodegeneration, interaction with other proteins, and development of potential therapies. You might also find related proteins beneficial, such as Recombinant human MOG (1-125).

Related Products

• Recombinant mouse MOG (1-125)
• EndoClear™ human recombinant a-Synuclein protein

Browse more in Catalog recombinant.